143 related articles for article (PubMed ID: 36944065)
1. Checkpoint Inhibitor-Associated Vogt-Koyanagi-Harada Disease Presenting 3 Months Following Discontinuation of Nivolumab.
Tieger MG; Eliott D; Cakir B; Dahrouj M
Ophthalmic Surg Lasers Imaging Retina; 2023 Mar; 54(3):183-187. PubMed ID: 36944065
[TBL] [Abstract][Full Text] [Related]
2. [Bilateral Nivolumab-associated Vogt-Koyanagi-Harada-like Uveitis in a Patient with Metastatic Renal Cell Carcinoma].
Czichos C; Wawrzynów B; Chamalis C; von Jagow B
Klin Monbl Augenheilkd; 2021 Jun; 238(6):711-714. PubMed ID: 33395707
[No Abstract] [Full Text] [Related]
3. BILATERAL DIFFUSE UVEAL MELANOCYTIC PROLIFERATION MISTAKEN FOR NIVOLUMAB-INDUCED VOGT-KOYANAGI-HARADA DISEASE-LIKE SYNDROME.
Dallinga MG; Bolhuis K; Bins A; de Hoog J
Retin Cases Brief Rep; 2024 May; 18(3):332-336. PubMed ID: 36728009
[TBL] [Abstract][Full Text] [Related]
4. Concurrent Vogt-Koyanagi-Harada disease and impressive response to immune checkpoint blockade in metastatic melanoma.
Gambichler T; Seifert C; Lehmann M; Lukas C; Scheel C; Susok L
Immunotherapy; 2020 May; 12(7):439-444. PubMed ID: 32308086
[No Abstract] [Full Text] [Related]
5. VOGT-KOYANAGI-HARADA DISEASE-LIKE UVEITIS IN A PATIENT WITH ADVANCED MELANOMA TREATED BY SEQUENTIAL ADMINISTRATION OF NIVOLUMAB AND DABRAFENIB/TRAMETINIB THERAPY.
Madoe A; Schauwvlieghe PP; Jacob J
Retin Cases Brief Rep; 2023 Sep; 17(5):611-615. PubMed ID: 37643052
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab-induced Vogt-Koyanagi-Harada-like Syndrome and Adrenocortical Insufficiency with Long-term Survival in a Patient with Non-small-cell Lung Cancer.
Ushio R; Yamamoto M; Miyasaka A; Muraoka T; Kanaoka H; Tamura H; Kaneko A; Izawa A; Hirama N; Teranishi S; Manabe S; Inoue T; Shibata K; Sugiura Y; Kudo M; Kaneko T
Intern Med; 2021 Nov; 60(22):3593-3598. PubMed ID: 34092725
[TBL] [Abstract][Full Text] [Related]
7. Vogt-Koyanagi-Harada-like syndrome in the setting of combined anti-PD1/anti-CTLA4 therapy.
Godse R; Mcgettigan S; Schuchter LM; Ellebrecht CT; Chu EY
Clin Exp Dermatol; 2021 Aug; 46(6):1111-1112. PubMed ID: 33846999
[No Abstract] [Full Text] [Related]
8. Vogt-Koyanagi-Harada disease-like uveitis following nivolumab administration treated with steroid pulse therapy: a case report.
Kikuchi R; Kawagoe T; Hotta K
BMC Ophthalmol; 2020 Jun; 20(1):252. PubMed ID: 32580711
[TBL] [Abstract][Full Text] [Related]
9. Vogt-Koyanagi-Harada syndrome-like uveitis after nivolumab administration as a treatment for ovarian cancer.
Hwang GE; Lee JW; Jeon S; Cho IH; Kim HD
Doc Ophthalmol; 2022 Apr; 144(2):153-162. PubMed ID: 34997406
[TBL] [Abstract][Full Text] [Related]
10. Ocular Adverse Events following Use of Immune Checkpoint Inhibitors for Metastatic Malignancies.
Noble CW; Gangaputra SS; Thompson IA; Yuan A; Apolo AB; Lee JM; Papaliodis GN; Kodati S; Bishop R; Magone MT; Sobrin L; Sen HN
Ocul Immunol Inflamm; 2020 Aug; 28(6):854-859. PubMed ID: 31013173
[TBL] [Abstract][Full Text] [Related]
11. Vogt-Koyanagi-Harada syndrome in two patients with immunoglobulin A nephropathy.
Matsuo T; Masuda I; Ota K; Yamadori I; Sunami R; Nose S
Acta Med Okayama; 2007 Oct; 61(5):305-9. PubMed ID: 17971847
[TBL] [Abstract][Full Text] [Related]
12. Vogt-Koyanagi-Harada-like syndrome induced by immune checkpoint inhibitors in a patient with melanoma.
Yoshida S; Shiraishi K; Mito T; Sayama K
Clin Exp Dermatol; 2020 Oct; 45(7):908-911. PubMed ID: 32394515
[No Abstract] [Full Text] [Related]
13. Case Report: Ipilimumab-induced Multisystem Autoimmune-like Toxicities Suggestive of Vogt-Koyanagi-Harada-like Syndrome.
Monferrer-Adsuara C; Hernández-Bel L; Hernández-Garfella ML; Remolí-Sargues L; Ortiz-Salvador M; Castro-Navarro V; Cervera-Taulet E
Optom Vis Sci; 2021 Nov; 98(11):1309-1316. PubMed ID: 34510146
[TBL] [Abstract][Full Text] [Related]
14. Case with metastatic cutaneous malignant melanoma that developed Vogt-Koyanagi-Harada-like uveitis following pembrolizumab treatment.
Enomoto H; Kato K; Sugawara A; Itabashi M; Kondo M
Doc Ophthalmol; 2021 Jun; 142(3):353-360. PubMed ID: 33392895
[TBL] [Abstract][Full Text] [Related]
15. A case presentation of an IgA nephropathy patient with Vogt-Koyanagi-Harada syndrome.
Zhang Q; Fan X; Tian M; Han H
BMC Nephrol; 2020 Jul; 21(1):272. PubMed ID: 32660433
[TBL] [Abstract][Full Text] [Related]
16. A case of Vogt-Koyanagi-Harada-like uveitis secondary to dabrafenib/trametinib therapy for advanced melanoma.
Brambati M; Giuffrè C; Marchese A; Bandello F; Modorati GM; Miserocchi E
Eur J Ophthalmol; 2022 Jan; 32(1):NP109-NP113. PubMed ID: 32998540
[TBL] [Abstract][Full Text] [Related]
17. Development of Vogt-Koyanagi-Harada disease-like uveitis during treatment by anti-programmed death-1 antibody: a case report.
Wang JN; Zhang Y; Huang CY; Li K; Yu XB
BMC Ophthalmol; 2024 Jun; 24(1):240. PubMed ID: 38849786
[TBL] [Abstract][Full Text] [Related]
18. Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case report.
Mari R; Guerin M; Vicier C; Walz J; Bonnet N; Pignot G; Gravis G
Front Immunol; 2022; 13():984132. PubMed ID: 36189265
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Ipilimumab-Induced Vogt-Koyanagi-Harada Syndrome With Oral Dexamethasone.
Witmer MT
Ophthalmic Surg Lasers Imaging Retina; 2017 Nov; 48(11):928-931. PubMed ID: 29121363
[TBL] [Abstract][Full Text] [Related]
20. [Vogt-Koyanagi-Harada-like uveitis under immune checkpoint inhibitor treatment for metastasized malignant melanoma].
Mihailovic N; Dyballa J; Herz S; Fluck M; Alnawaiseh M; Merté RL; Eter N
Ophthalmologe; 2020 May; 117(5):467-471. PubMed ID: 31489479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
